BioSkryb Genomics, a leader in single-cell and ultra-low-input multi-omic technologies, has secured an exclusive license to a groundbreaking patent co-owned by Stanford University and the Chan Zuckerberg Biohub San Francisco (CZ Biohub SF). The patent covers a novel method for simultaneously analyzing DNA methylation and genomic variants at single-cell resolution using a non-destructive workflow that preserves DNA integrity. The technology, developed at Stanford, enables researchers to obtain high-resolution, genome-wide insights into both epigenetic modifications and genetic variation from the same individual cell. This capability is particularly transformative for studying complex biological processes such as clonal evolution, therapy resistance, and the emergence of precursor lesions in diseases like cancer and neurological disorders. “This license directly addresses a critical demand from researchers who need to link epigenetic state with genetic variation in the same cell without compromising sample quality,” said Suresh Pisharody, CEO of BioSkryb Genomics. “By enabling same-cell analysis, we empower scientists to gain confidence in their findings—especially when tracking how genetic and epigenetic changes co-evolve over time. We are committed to bringing this exclusive capability to market as quickly and rigorously as possible.” The licensed technology will form the foundation for BioSkryb’s next-generation products, allowing researchers to simultaneously assess genomic variants, DNA methylation, the transcriptome, and surface proteome within a single, integrated workflow. This modular approach represents a major leap forward in single-cell multi-omic analysis. To help researchers make sense of the complex, high-dimensional data generated by these advanced platforms, BioSkryb is investing heavily in artificial intelligence and machine learning. These tools will enable the integration of multi-omic datasets into interpretable biological insights and the discovery of novel biomarkers—addressing a growing need as single-cell datasets expand in size and complexity. “Combining methylation and variant analysis in the same cell transforms single-cell biology from fragmented snapshots to a complete molecular picture,” said Charles (Chuck) Gawad, MD, PhD, Chief Scientific Officer and Founder of BioSkryb Genomics. “When you can see both genetic changes and epigenetic regulation in concert, you can better understand cause and effect in disease progression—accelerating discovery and advancing precision medicine.” Melinda Griffith, Chief Operating Officer at CZ Biohub SF, emphasized the broader impact of the licensing agreement. “At CZ Biohub SF, our mission is to accelerate discovery and responsibly translate breakthroughs for the public good. By licensing this innovative method to BioSkryb, we’re expanding access to powerful new tools that will empower researchers worldwide and ultimately benefit patients.” Based in Durham, North Carolina, BioSkryb Genomics is at the forefront of transforming single-cell analysis with its advanced amplification technologies. The company’s tools and services provide unprecedented resolution into the genome, transcriptome, and targeted proteins at the single-cell level, helping scientists uncover the molecular drivers of complex diseases and paving the way for more effective diagnostics and treatments. For more information, visit bioskryb.com.